Sara C. M. Stoof
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sara C. M. Stoof has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Anders Boyd
Stichting HIV Monitoring Amsterdam The Netherlands
4 shared publications - Katrijn Daenen
Department of Adult Intensive Care, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands
4 shared publications - Diederik Gommers
Erasmus MC
3 shared publications - Eric C. M. van Gorp
Department of Viroscience, Erasmus Medical Center, 3015 GD Rotterdam, the Netherlands
3 shared publications F. W. G. Leebeek
Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
3 shared publications- Henrik Endeman
Department of Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 26 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70427
Inflammatory Biomarkers as Mediators of the Effect Between High‐Dose Corticosteroid Therapy and Mortality in COVID‐19‐Related ARDS: A Causal Mediation Analysis
Background: Treatment guidelines for acute respiratory distress syndrome (ARDS) recommend the use of high‐dose corticosteroids based on their anti‐inflammatory effects, yet the efficacy of this therapeutic strategy in patients with COVID‐19 related ARDS is inconclusive. To more thoroughly understand the mechanism of action for high‐dose corticosteroids in patients with COVID‐19‐related ARDS, we hypothesized that the reduction of inflammatory markers induced by high‐dose corticosteroids would reduce mortality (i.e., inflammation as a mediator). Design and Methods: In this retrospective cohort study, we included patients with COVID‐19‐related ARDS admitted to the intensive care unit (ICU) of an academic hospital in Rotterdam, the Netherlands between March 2020 and June 2022. High‐dose corticosteroids were defined as > 6 mg of dexamethasone/day or equivalent. Biomarkers included C‐reactive protein (CRP), d ‐dimer, ferritin, leukocyte count, interleukin‐6 (IL‐6), lactate dehydrogenase, and neutrophil‐to‐lymphocyte ratio (NLR). Using a causal mediation framework, we estimated the average mediation effect (AME) and % mediation for each biomarker, allowing to quantify the degree to which continuous levels of inflammatory markers mediate the association between receiving high‐dose corticosteroids and mortality. The models used in this framework accounted for time‐varying treatment/mediation with inverse probability of treatment weights, determined from the covariates PaO 2 /FiO 2 ratio, sex at birth, age, NLR, and ICU length of stay. Results: Of the 327 patients included, 122 (37.3%) received high‐dose corticosteroids. The risk of death was higher in patients who did vs. did not receive high‐dose corticosteroids [incidence rate = 0.54, 95% confidence interval (CI) = 0.42–0.71 and 0.21, 95% CI = 0.15–0.29/person‐month, respectively; p < 0.001]. This effect remained in most analyses accounting for time‐varying treatment/mediation. The association between high‐dose corticosteroids and mortality was reduced (i.e., mediated) with lower levels of CRP (AME = −0.006, 95% CI = −0.011, −0.002; %‐mediation = −82.0%), d ‐dimer (AME = −0.002, 95% CI = −0.005, −0.001; %‐mediation = −33.1%), and IL‐6 (AME = −0.002, 95% CI = −0.004, −0.001; %‐mediation = −25.5%). There was no evidence of mediation for other biomarkers. Conclusion: CRP, d ‐dimer, and IL‐6 mediated the association between high‐dose corticosteroids and mortality. When inflammation was reduced, the deleterious effect of high‐dose corticosteroids was eliminated.
- 26 April 2026
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 14 (4) , e70427
Open AccessInflammatory Biomarkers as Mediators of the Effect Between High‐Dose Corticosteroid Therapy and Mortality in COVID‐19‐Related ARDS: A Causal Mediation Analysis
Background: Treatment guidelines for acute respiratory distress syndrome (ARDS) recommend the use of high‐dose corticosteroids based on their anti‐inflammatory effects, yet the efficacy of this therapeutic strategy in patients with COVID‐19 related ARDS is inconclusive. To more thoroughly understand the mechanism of action for high‐dose corticosteroids in patients with COVID‐19‐related ARDS, we hypothesized that the reduction of inflammatory markers induced by high‐dose corticosteroids would reduce mortality (i.e., inflammation as a mediator). Design and Methods: In this retrospective cohort study, we included patients with COVID‐19‐related ARDS admitted to the intensive care unit (ICU) of an academic hospital in Rotterdam, the Netherlands between March 2020 and June 2022. High‐dose corticosteroids were defined as > 6 mg of dexamethasone/day or equivalent. Biomarkers included C‐reactive protein (CRP), d ‐dimer, ferritin, leukocyte count, interleukin‐6 (IL‐6), lactate dehydrogenase, and neutrophil‐to‐lymphocyte ratio (NLR). Using a causal mediation framework, we estimated the average mediation effect (AME) and % mediation for each biomarker, allowing to quantify the degree to which continuous levels of inflammatory markers mediate the association between receiving high‐dose corticosteroids and mortality. The models used in this framework accounted for time‐varying treatment/mediation with inverse probability of treatment weights, determined from the covariates PaO 2 /FiO 2 ratio, sex at birth, age, NLR, and ICU length of stay. Results: Of the 327 patients included, 122 (37.3%) received high‐dose corticosteroids. The risk of death was higher in patients who did vs. did not receive high‐dose corticosteroids [incidence rate = 0.54, 95% confidence interval (CI) = 0.42–0.71 and 0.21, 95% CI = 0.15–0.29/person‐month, respectively; p < 0.001]. This effect remained in most analyses accounting for time‐varying treatment/mediation. The association between high‐dose corticosteroids and mortality was reduced (i.e., mediated) with lower levels of CRP (AME = −0.006, 95% CI = −0.011, −0.002; %‐mediation = −82.0%), d ‐dimer (AME = −0.002, 95% CI = −0.005, −0.001; %‐mediation = −33.1%), and IL‐6 (AME = −0.002, 95% CI = −0.004, −0.001; %‐mediation = −25.5%). There was no evidence of mediation for other biomarkers. Conclusion: CRP, d ‐dimer, and IL‐6 mediated the association between high‐dose corticosteroids and mortality. When inflammation was reduced, the deleterious effect of high‐dose corticosteroids was eliminated.
- Open Access
- 23 January 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (2)
Prediction Models for Mortality in Patients With Moderate to Severe ARDS Treated in the ICU
- 23 January 2025
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (2)
Open AccessPrediction Models for Mortality in Patients With Moderate to Severe ARDS Treated in the ICU
- Open Access
- 2 June 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12, e48183
Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT)
Background: In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. Objective: Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. Methods: This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. Results: As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024. Conclusions: This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment. Trial Registration: ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359 International Registered Report Identifier (IRRID): DERR1-10.2196/48183
- 2 June 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12, e48183
Open AccessOptimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT)
Background: In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. Objective: Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. Methods: This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. Results: As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024. Conclusions: This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment. Trial Registration: ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359 International Registered Report Identifier (IRRID): DERR1-10.2196/48183
- Open Access
- 14 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT) (Preprint)
BACKGROUND In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. OBJECTIVE Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. METHODS This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. RESULTS As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024. CONCLUSIONS This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment. CLINICALTRIAL ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48183
- 14 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessOptimal Dosing and Timing of High-Dose Corticosteroid Therapy in Hospitalized Patients With COVID-19: Study Protocol for a Retrospective Observational Multicenter Study (SELECT) (Preprint)
BACKGROUND In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. OBJECTIVE Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. METHODS This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. RESULTS As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024. CONCLUSIONS This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment. CLINICALTRIAL ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48183
- 21 June 2017
- Published by Wiley in Haemophilia
- Vol. 23 (6) , 861-867
Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen
Introduction: Due to interindividual variation in desmopressin response, non‐severe haemophilia A patients require desmopressin testing prior to therapeutic treatment. However, adequate response or frequency of blood sampling is not standardised in international guidelines. Consequently, various definitions and blood sampling protocols are currently applied. Interestingly, sustainability of desmopressin response is not incorporated into these definitions.Aim: To study desmopressin response rates in a cohort of non‐severe haemophilia A patients using currently accepted desmopressin response definitions. This, in order to formulate a standardised, uniform response which includes information on sustainability and to design a standardised blood sampling protocol.Methods: Currently used desmopressin responses in non‐severe haemophilia A patients were derived from a literature search. Actual desmopressin response rates were individualised in 105 non‐severe HA patients from the Erasmus University Medical Centre and classified according to current varying definitions.Results: Five response definitions were evaluated, three of which included only factor VIII (FVIII):C cut‐off levels and two also incorporated FVIII:C‐fold increase over baseline. FVIII:C‐fold increase showed no association with desmopressin response sustainability. FVIII:C 1 hour after infusion (<0.30, ≥0.30‐0.49, ≥0.50‐0.79 and ≥0.80 IU/mL) was, however, indicative of desmopressin response after 6 hours.Conclusion: We suggest standardised desmopressin response based on clinically relevant FVIII:C levels, e.g. 0.30 and 0.50 IU/mL. In addition, patients with <0.30 IU/mL FVIII:C after 1 hour (non‐responder) or ≥0.80 IU/mL (sustained responder) do not require subsequent blood sampling. However, patients with ≥0.30‐0.79 IU/mL FVIII:C after 1 hour should undergo blood sampling after 6 hours to additionally determine response sustainability.
- 21 June 2017
- Published by Wiley in Haemophilia
- Vol. 23 (6) , 861-867
Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen
Introduction: Due to interindividual variation in desmopressin response, non‐severe haemophilia A patients require desmopressin testing prior to therapeutic treatment. However, adequate response or frequency of blood sampling is not standardised in international guidelines. Consequently, various definitions and blood sampling protocols are currently applied. Interestingly, sustainability of desmopressin response is not incorporated into these definitions.Aim: To study desmopressin response rates in a cohort of non‐severe haemophilia A patients using currently accepted desmopressin response definitions. This, in order to formulate a standardised, uniform response which includes information on sustainability and to design a standardised blood sampling protocol.Methods: Currently used desmopressin responses in non‐severe haemophilia A patients were derived from a literature search. Actual desmopressin response rates were individualised in 105 non‐severe HA patients from the Erasmus University Medical Centre and classified according to current varying definitions.Results: Five response definitions were evaluated, three of which included only factor VIII (FVIII):C cut‐off levels and two also incorporated FVIII:C‐fold increase over baseline. FVIII:C‐fold increase showed no association with desmopressin response sustainability. FVIII:C 1 hour after infusion (<0.30, ≥0.30‐0.49, ≥0.50‐0.79 and ≥0.80 IU/mL) was, however, indicative of desmopressin response after 6 hours.Conclusion: We suggest standardised desmopressin response based on clinically relevant FVIII:C levels, e.g. 0.30 and 0.50 IU/mL. In addition, patients with <0.30 IU/mL FVIII:C after 1 hour (non‐responder) or ≥0.80 IU/mL (sustained responder) do not require subsequent blood sampling. However, patients with ≥0.30‐0.79 IU/mL FVIII:C after 1 hour should undergo blood sampling after 6 hours to additionally determine response sustainability.
- 12 May 2017
- Published by Wiley in Haemophilia
- Vol. 23 (4) , e355-e358
Sensor‐based gait analysis as a simple tool to measure gait in haemophilia patients
- 12 May 2017
- Published by Wiley in Haemophilia
- Vol. 23 (4) , e355-e358
Sensor‐based gait analysis as a simple tool to measure gait in haemophilia patients
- 16 February 2015
- Published by Wiley in Haemophilia
- Vol. 21 (4) , 505-512
Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey
Summary: Pregnant women with bleeding disorders require specialised peripartum care to prevent postpartum haemorrhage (PPH). If third trimester coagulation factor levels are −1, prophylactic treatment is indicated and administered according to international guidelines. However, optimal dose and duration are unknown and bleeding may still occur. The aim of this study was to investigate the outcome in women with von Willebrand disease (VWD) or haemophilia carriership treated according to current practice guidelines. From the period 2002–2011, 185 deliveries in 154 VWD women or haemophilia carriers were retrospectively included. Data on blood loss, bleeding disorder characteristics and obstetric risk factors were obtained. The outcome was primary PPH, defined as blood loss ≥500 mL within 24 h postpartum and severe PPH as blood loss ≥1000 mL. Primary PPH was observed in 62 deliveries (34%), 14 (8%) of which resulted in severe PPH. In 26 deliveries prophylactic treatment was administered due to factor levels below the 0.50 IU mL−1 cut‐off in the third trimester, 14 of which (54%) were complicated by PPH. We found an increased PPH risk in deliveries given prophylactic treatment compared with deliveries without (OR 2.7, 95% CI 1.2–6.3). In conclusion, PPH incidence was highest in deliveries with the lowest factor levels in the third trimester. Currently, delivery outcome in women with bleeding disorders is unsatisfactory, given the high PPH incidence despite specialised care. Future studies are required to optimise management of deliveries in this patient population.
- 16 February 2015
- Published by Wiley in Haemophilia
- Vol. 21 (4) , 505-512
Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey
Summary: Pregnant women with bleeding disorders require specialised peripartum care to prevent postpartum haemorrhage (PPH). If third trimester coagulation factor levels are −1, prophylactic treatment is indicated and administered according to international guidelines. However, optimal dose and duration are unknown and bleeding may still occur. The aim of this study was to investigate the outcome in women with von Willebrand disease (VWD) or haemophilia carriership treated according to current practice guidelines. From the period 2002–2011, 185 deliveries in 154 VWD women or haemophilia carriers were retrospectively included. Data on blood loss, bleeding disorder characteristics and obstetric risk factors were obtained. The outcome was primary PPH, defined as blood loss ≥500 mL within 24 h postpartum and severe PPH as blood loss ≥1000 mL. Primary PPH was observed in 62 deliveries (34%), 14 (8%) of which resulted in severe PPH. In 26 deliveries prophylactic treatment was administered due to factor levels below the 0.50 IU mL−1 cut‐off in the third trimester, 14 of which (54%) were complicated by PPH. We found an increased PPH risk in deliveries given prophylactic treatment compared with deliveries without (OR 2.7, 95% CI 1.2–6.3). In conclusion, PPH incidence was highest in deliveries with the lowest factor levels in the third trimester. Currently, delivery outcome in women with bleeding disorders is unsatisfactory, given the high PPH incidence despite specialised care. Future studies are required to optimise management of deliveries in this patient population.